What could possibly go wrong? It’s growth-oriented, with steadily increasing sales, and operates in the obesity management space. It would only become a bad investment if widespread poverty from an economic depression became the default method of... — read more 

However, I’m reluctant to buy. Primary driver of the stock price seemed to be Ozempic. Weight-reduction dr-gs, therapies, diets have always had a short lifespan. It seems to me that Ozempic popularity is already waning, and that’s reflecting on the... — read more 

GLP-1 dr-gs have helped people lose weight, but they can have other positive effects. A recent study found that they could help with Alzheimer's disease. Novo Nordisk's business could get a boost from products besides Ozempic and... — read more